Physician profile
Eisha Wali
NPI 1932580529
$2,721.60
in general payments reported to CMS, 2019-2025
23 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $163 · 2021: $392 · 2022: $569 · 2023: $539 · 2024: $201 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $687.96 | 2019-2025 | Optis, Coroflow, Dragonfly Opstar |
| Astrazeneca Pharmaceuticals LP | $354.24 | 2021-2025 | Wainua, Lokelma |
| Janssen Pharmaceuticals, INC | $201.95 | 2019-2023 | Xarelto |
| Pfizer INC. | $192.83 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $171.45 | 2019-2024 | Lifevest |
| Heartflow, INC. | $137.52 | 2023 | Ffrct |
| Amgen INC. | $126.52 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $119.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $115.15 | 2022-2025 | |
| Lantheus Medical Imaging, INC. | $103.15 | 2020-2023 | Definity |
| E.R. Squibb & Sons, L.L.C. | $84.20 | 2023-2025 | Camzyos |
| Novo Nordisk INC | $70.36 | 2024-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.51 | 2024 | Jardiance |
| Cardiva Medical, INC. | $59.39 | 2023 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs |
| Boston Scientific Corporation | $51.70 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $33.56 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $30.53 | 2022 | |
| Bridgebio Pharma, INC. | $28.18 | 2025 | Attruby |
| Akcea Therapeutics, INC. | $21.39 | 2019 | |
| Terumo Medical Corporation | $21.36 | 2019 | |
| Merck Sharp & Dohme LLC | $15.51 | 2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $14.62 | 2019 | |
| Medtronic Vascular, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eisha Wali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.